
OBSV
Healthcare · Biotechnology & Medical Research · $11.0M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2022
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| May 17, 2023 | Time not confirmed | -0.06 | 0.00 | +100.0% |
| Mar 31, 2023 | Before the open | -0.06 | 0.25 | +516.7% |
| Dec 1, 2022 | After the close | -0.08 | -0.13 | -62.5% |
| Aug 17, 2022 | After the close | -0.17 | -0.39 | -129.4% |
| May 16, 2022 | After the close | -0.20 | -0.14 | +30.0% |
| Mar 9, 2022 | After the close | -0.22 | -0.26 | -18.2% |
| Nov 3, 2021 | After the close | -0.22 | 0.01 | +104.5% |
| Aug 4, 2021 | After the close | -0.25 | -0.25 | 0.0% |
| May 5, 2021 | After the close | -0.28 | -0.29 | -3.6% |
| Mar 4, 2021 | After the close | -0.42 | -0.32 | +23.8% |
| Nov 4, 2020 | After the close | -0.34 | -0.49 | -44.1% |
| Aug 5, 2020 | After the close | -0.42 | -0.38 | +9.5% |
| May 5, 2020 | Time not confirmed | -0.48 |
ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in…
| -0.48 |
| 0.0% |
| Mar 4, 2020 | After the close | -0.58 | -0.48 | +17.2% |
| Nov 6, 2019 | After the close | -0.82 | -0.63 | +23.2% |
| Aug 6, 2019 | After the close | -0.60 | -0.80 | -33.3% |
| May 8, 2019 | After the close | -0.51 | -0.59 | -15.7% |
| Mar 4, 2019 | After the close | -0.49 | -0.46 | +6.1% |
| Nov 7, 2018 | After the close | -0.46 | -0.42 | +8.7% |
| Aug 7, 2018 | After the close | -0.53 | -0.49 | +7.5% |
| May 16, 2018 | Before the open | -0.47 | -0.54 | -14.9% |
| Mar 9, 2018 | Before the open | -0.56 | -0.48 | +14.3% |